Skip to main content
. Author manuscript; available in PMC: 2009 Jul 21.
Published in final edited form as: Vaccine. 2007 Oct 26;25(51):8562–8573. doi: 10.1016/j.vaccine.2007.10.017

Figure 1.

Figure 1

Figure 1

Figure 1, Panel A: Percentage of local adverse events experienced by subjects according to the number of vaccinations received and group assignment.

Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax

B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax

C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax

D. SC Placebo/Placebo/Dryvax

E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo

F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax

Figure 1, Panel B: Percentage of systemic adverse events experienced by subjects according to the number of vaccinations received and group assignment.

Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax

B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax

C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax

D. SC Placebo/Placebo/Dryvax

E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo

F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax